
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is a strong investment opportunity with a diverse market presence and an attractive position in both the clinical diagnostics and life sciences markets, with potential for accelerated sales growth and improved margins. The company also possesses valuable optionality through its 33% ownership stake in Sartorius, which is set to increase in value once the Sartorius Trust terminates in mid-2028. While there are risks associated with market recovery and potential share losses in specific areas, overall corporate governance and sustainability integration remain as the biggest concerns for investors. With a strong management team and potential for margin expansion, our outlook on Bio-Rad Laboratories remains positive.
Bears say
Bio-Rad Laboratories is experiencing significant restructuring and management changes, with recent targets of a mid-teens EBIT margin and potential improvements in sales growth through the lapping of headwinds. However, concerns remain over its ownership stake in Sartorius and limited sustainability integration. Investors should keep a close eye on the company's progress as the potential for increased optionality in mid-2028 could drive future value.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares